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The chemokine receptor 5 ∆32 mutation is associated with in-
creased renal survival in patients with IgA nephropathy.
Background. Chemokine receptor 5 (CCR5) plays an im-
portant role in the recruitment of monocytes and T cells in in-
flammation and experimental studies suggest that CCR5 might
be involved in the pathogenesis of IgA nephropathy. A muta-
tion in the CCR5 gene (CCR5 32), leading to a nonfunctional
receptor, was recently described. We therefore evaluated the
potential role of this mutation on renal survival in patients with
IgA nephropathy.
Methods. The distribution of the CCR5 32 genotype was de-
termined by polymerase chain reaction (PCR) analysis in 228
patients with biopsy-proven IgA nephropathy. In 190 patients
with available demographic and clinical follow-up data, the ef-
fect of the mutation on the clinical outcome was analyzed using
the Log-rank test and the Cox proportional hazard model. In
vitro, the influence of the CCR5 32 genotype on the chemo-
tactic response of monocytes was assessed.
Results. Of the 190 patients, 158 (83.2%) had a CCR5 wild-
type genotype, 29 (15.3%) were heterozygous, and three pa-
tients had a homozygous CCR5 32 genotype (1.6%). Renal
survival was significantly longer in patients with the CCR5 32
genotype than in the wild-type group (Log-rank P < 0.001).
Using the multivariate Cox proportional hazard model, the
CCR5 32 genotype was identified as an independent factor
associated with a lower risk to develop end-stage renal disease
(ESRD) [hazard ratio (HR) 0.23, 95% CI 0.09 to 0.57, P =
0.002]. In vitro analysis of monocytes from CCR5 32 carri-
ers showed a reduced chemotactic response to CCR5 ligands in
vitro.
Conclusion. Our study demonstrates an independent role
of the CCR5 32 genotype for the clinical outcome in IgA
nephropathy. In vitro experiments revealed a reduced chemo-
tactic response of monocytes from CCR5 32 carriers, thus
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pointing out a possible pathophysiologic explanation for the
beneficial effect of the CCR5 32 genotype.
The infiltration of inflammatory leukocytes into the
glomerulus and the renal tubulointerstitium are hall-
marks of most forms of human glomerulonephritis [1,
2]. Inflammatory cell infiltrates mediate injury and re-
pair. This is also true in patients with IgA nephropa-
thy, the most frequent form of glomerulonephritis in the
world. The clinical course of IgA nephropathy is charac-
terized by stable renal function in the majority of patients.
One third of the patients, however, loses renal function
and progresses to end-stage renal disease (ESRD) [3–5].
Although the mechanisms responsible for disease pro-
gression are largely unknown a correlation between the
presence of mononuclear inflammatory cells (monocytes
and lymphocytes) in renal tissue and the progression of
the disease exists [6–8].
Chemokines, a group of chemotactic cytokines, play a
central role in the recruitment of leukocytes [9]. Their ef-
fects are mediated through chemokine receptors, which
are predominantly expressed on leukocytes [9, 10]. An
important receptor on monocytes and T cells is the
chemokine receptor 5 (CCR5). Experimental data in an-
imals show that blockade of the CCR5 receptor with a
peptide antagonist reduces glomerular leukocyte infiltra-
tion and ameliorates the development of renal injury [11].
Importantly, the number of infiltrating CCR5-positive
leukocytes into the kidney is positively correlated with
loss of renal function in IgA nephropathy, suggesting a
role for CCR5 in the pathophysiology of this glomeru-
lonephritis [12].
Recently, a 32 bp deletion mutation in the CCR5 gene
(CCR5 32) was described which leads to a nonfunc-
tional receptor. The CCR5 32 allele frequency is be-
tween 0.04 and 0.16 of humans in Europeans [13]. The
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high allelic frequency of CCR5 32 in the European and
North American population cannot be explained through
random genetic drift, suggesting an unknown selection
advantage of allele carriers [13]. Homozygous carriers
appear to be healthy and are protected against human
immunodeficiency virus (HIV) infection since the CCR5
is a coreceptor for the M trophic variant of HIV [14–
16]. Other, preliminary reports demonstrated a reduced
CCR5 32 allele frequency in patients with asthma [17].
In rheumatoid arthritis, disease severity was reduced in
patients carrying the CCR5 32 genotype [18]. A prolon-
gation of renal transplant survival was found in patients
with the homozygous form of the CCR5 32 mutation
[19]. These data suggest an important role of the CCR5
in diseases characterized by the recruitment of mononu-
clear cells.
The aim of our study was to evaluate the effect of
the CCR5 32 genotype on the clinical course of pa-
tients with IgA nephropathy. A total of 190 patients
from German Nephrology centers with biopsy-proven
IgA nephropathy and clinical follow-up data were in-
cluded in the study and the effect of the mutation on
renal survival was analyzed. In an attempt to determine
possible pathophysiologic differences we assessed the in-
fluence of the CCR5 32 genotype on monocyte chemo-
taxis in in vitro studies.
METHODS
Study cohort and data acquisition
Between January 1999 and March 2002, we screened
228 IgA nephropathy patients from 25 German Nephrol-
ogy centers. All patients gave informed consent for CCR5
genotype analysis. Approval for the study was given by
the local ethics committee on October 19, 1998 and has
been conducted according to the Declaration of Helsinki
principles.
Only Caucasian patients with a histologically proven
primary IgA nephropathy who had been diagnosed by
light microscopy and immunohistology were included
in the study. Patients with secondary causes of IgA
nephropathy (Henoch-Scho¨nlein purpura, liver cirrhosis,
lupus nephritis, and diabetic nephropathy) were not in-
cluded. Thirty-eight patients were excluded after primary
recruitment because of lack of clinical follow-up data.
The following demographic and clinical data were
retrospectively assessed from the clinical records at
the timepoint of recruitment: Age, gender, proteinuria
(>1 g/24 hours), serum creatinine (mg/dL), and blood
pressure [presence or absence of hypertension (systolic
blood pressure greater than 140 mmHg) or prescrip-
tion of antihypertensive treatment] all at the time point
of renal biopsy. The study end point was ESRD de-
fined through start of renal replacement therapy. Dial-
ysis was initiated in accordance to the European Renal
Association-European Dialysis and Transplantation As-
sociation guidelines [20]. Renal survival was defined as
absence of renal replacement therapy during the follow-
up period. Time of follow-up was the time between renal
biopsy (establishing the diagnosis of IgA nephropathy)
and either the last clinical follow-up of the patient with
renal survival during the study period (March 2002), or
the start of renal replacement therapy in those patients
who reached the end point of the study. No death was
reported in the follow-up period.
Detection of CCR5 ∆32 allele frequency
Genomic DNA was isolated from peripheral blood
leukocytes using a commercial kit (Qiagen, Hilden,
Germany). Purified genomic DNA (50 ng) was amplified
by polymerase chain reaction (PCR) using the following
primers: forward primer CAA AAA GAA GGT CTT
CAT TAC ACC, reverse primer CCT GTG CCT CTT
CTT CTC ATT TCG. To 50 ng of genomic DNA, 29.5 lL
H2O, 5 lL 10 × PCR buffer, 3 lL MgCl2 (25 mmol/L), 4
lL deoxynucleoside triphosphate (dNTP) (2.5 mmol/L),
1.5 lL forward primer (50 ng/mL), 1.5 lL reverse primer
(50 ng/mL), and 0.5 lL Taq DNA Polymerase (5 U/mL)
(Promega, Madison, WI, USA) were added. PCR was
run for 32 cycles using the following temperature pro-
file: denaturation at 95◦C for 10 seconds, annealing for
20 seconds at 60◦C, and extension for 30 seconds at 72◦C.
The length of the amplified fragment was 215 bp for the
wild-type and 183 bp for the CCR5 32 allele. The PCR
fragments were separated on a 1.5% agarose gel and pa-
tients classified as weight (+/+), weight/32 (+/−), and
32/32 (−/−). Genotypes of random samples were de-
termined by automatic DNA sequencing and showed re-
sults identical to the gel electrophoresis analysis (data not
shown).
Chemotactic assays
To evaluate the effects of the CCR5 32 mutation
on chemotaxis we analyzed the chemotactic potency of
the CCR5 chemokine ligands regulated upon activa-
tion, normal T cell expressed and secreted (RANTES),
macrophage inflammatory protein (MIP)-1a, MIP-1b ,
and monocyte chemoattractant protein (MCP)-1 (R&D
Systems, Minneapolis, MN, USA) on freshly isolated hu-
man monocytes from CCR5 wild-type, heterozygous, and
homozygous 32 carriers (3 × 106 cells/mL) in Boyden
microchambers [21]. The number of migrating monocytes
was used as a parameter to estimate the chemotactic re-
sponse.
Statistical methods
Results are expressed as mean ± SD unless stated oth-
erwise. Statistical significance was defined as P < 0.05
or in case of k comparisons P < 0.05/k (Bonferroni
adjustment).
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Fig. 1. CCR5 genotype analysis. Example of genotype analysis to de-
termine the presence of the CCR5 32 mutation in patients with IgA
nephropathy. The length of the amplified fragment is 215 bp for the
wild-type and 183 bp for the CCR5 32 allele. The polymerase chain
reaction (PCR) fragments were separated on a 1.5% agarose gel and
patients classified as wild-type (+/+), heterozygous (+/−), and homozy-
gous (−/−) carrier.
To compare continuous variables of two distinct
groups, we applied the Mann-Whitney test. For compar-
ison of nominal variables, the v 2 test was used.
To test whether the CCR5 32 allele frequency in
the IgA collective was lower than in the healthy control
group, we compared the two groups using the two-sided
Fisher’s exact test.
The influence of the CCR5 32 genotype on renal sur-
vival of patients with IgA nephropathy was analyzed by
Kaplan-Meier plot and Log-rank test.
The effects of the CCR5 32 genotype, serum crea-
tinine, proteinuria, hypertension, gender, and age at the
time of biopsy on renal survival were evaluated by uni-
variate Cox proportional hazard analysis. Covariates with
P < 0.05 in univariate analysis were entered into multi-
variate Cox proportional hazard analysis. For multivari-
ate analysis forward conditional entry was used. P values
were derived by theWald v 2 test.
Differences in chemotaxis between the three groups
(CCR5+/+, +/32, 32/32) were compared by
Kruskal-Wallis test with post hoc analysis by Mann-
Whitney test.
For all statistical survival analyses, the genotype was
defined as presence or absence of the CCR5 mutated
32 allele. Statistical analyses were performed using the
statistic program SPSS 10.1.3.
RESULTS
CCR5 genotyping
Presence of the CCR5 32 genotype was determined
by PCR (Fig. 1). For the 190 IgA nephropathy patients
included in the study the genotypes were as follows: 158
(83.2%) patients had a CCR5 wild-type, 29 (15.3%) were
heterozygous carriers of the mutation, and three patients
had a homozygous CCR5 32 genotype (1.6%). The al-
lelic frequency of the 32 deletion was therefore 0.092.
Thirty-eight patients were excluded from the study for
lack of clinical follow-up data. The CCR5 32 genotype
distribution was as follows: 32 (84.2%) patients had a
CCR5 wild-type genotype, six (15.8%) were heterozy-
gous carriers, and no patient (0%) had a homozygous
CCR5 32 genotype. The 32 allelic frequency in this
group was 0.079.
To analyze the distribution of the CCR5 32 allele in
a control collective, a random selection of 651 German
healthy blood donors was screened after confirmed con-
sent to analyze their CCR5 genotype. Of those, 498
(76.5%) were CCR5 wild-type carriers, 144 (22.1%) were
heterozygous for the 32 mutation, and nine (1.4%) in-
dividuals showed homozygosity. Genotype distribution
in both collectives was according to the Hardy-Weinberg
equilibrium. There was a nonsignificant tendency for an
increased allele frequency in the control group (0.124) in
comparison to the IgA collective (P = 0.08 by two-sided
Fisher’s exact test).
Demographic and clinical data of the study cohort
Table 1 shows an overview of the demographic and
clinical data assessed [age in years, gender, hypertension,
serum creatinine level, and proteinuria (>1 g/24 hours)]
at the time point of renal biopsy, as well as the follow-up
in months, and the percentage of ESRD development.
At the time point of renal biopsy, the characteristics of
the patients in the two groups were similar, with the ex-
ception of a significantly higher serum creatinine level in
the CCR5 wild-type group. The percentage of ESRD de-
velopment was also higher in the CCR5 wild-type group.
The follow-up time in months was significantly longer in
the CCR5 32 patient group.
Effects of the CCR5 genotype on the clinical course
in IgA nephropathy
Analysis of cumulative renal survival by Kaplan-Meier
plot with subsequent Log-rank test showed a significantly
longer survival in the group of IgA nephropathy patients
carrying the CCR5 32 genotype (N = 32) in comparison
to the wild-type group (N = 158) (P < 0.001) (Fig. 2).
The prognostic value of serum creatinine level, 24-hour
proteinuria, hypertension, age, gender, and CCR5 geno-
type on renal survival in patients with IgA nephropa-
thy was evaluated by univariate Cox proportional hazard
analysis. Our results confirm earlier studies showing that
the serum creatinine value at the time of biopsy is the ma-
jor prognostic factor for clinical outcome. Interestingly,
in our collective of IgA nephropathy patients the CCR5
32 genotype is the second most important prognostic
factor for renal survival. Age, hypertension, gender, and
proteinuria (>1 g/24 hours at the time of renal biopsy)
were not prognostic factors in univariate analysis.
Serum creatinine and CCR5 32 genotype were en-
tered into multivariate Cox proportional hazard analysis
to test if both covariates are prognostic factors for renal
survival independent of each other. Multivariate analysis
by three different models (enter, forward conditional en-
try, and backward conditional exclusion) supported the
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Table 1. Demographic and clinical data of the study cohort
CCR5 32 genotype P value
CCR5 wild-type (+/+) (+/32 and 32/32) Total weight vs.
83.2% (N = 158) 16.9% (N = 32) 100% (N = 190) 32 genotype
Age at biopsy years Mean 39.1 ± 14.2 Mean 40.8 ± 14.3 Mean 39.4 ± 14 0.35 (NS)
Median 39 (10–85) Median 44.5 (16–62) Median 40 (10–85)
(N = 146) (N = 28) (N = 174)
Gender% male 74.7% 78.1% 75.3% 0.82 (NS)
(N = 158) (N = 32) (N = 190)
Hypertension at biopsy 74.1% 64.2% 72.1% 0.36 (NS)
(systolic blood pressure >140 mm Hg) (N = 137) (N = 28) (N = 165)
Proteinuria at biopsy 67% 63% 67.5% 0.65 (NS)
(>1 g/24 hours) (N = 133) (N = 27) (N = 160)
Creatinine at biopsy Mean 2.6 ± 1.7 Mean 1.7 ± 1.5 Mean 2.4 ± 1.9 0.001
mg/dL Median 2,2 (0.8–10.5) Median 1.2 (0.5–6.9) Median 1.9 (0.5–10.5)
(N = 136) (N = 29) (N = 165)
Follow-up months Mean 48.1 ± 48.3 Mean 65,9 ± 54.0 Mean 51 ± 49.6 0.042
Median 31.5 (1–216) Median 50.5 (1–190) Median 33.5 (1–216)
(N = 158) (N = 32) (N = 190)
Development of end-stage renal disease 57.6% 21.9% 51.6% <0.001
(N = 158) (N = 32) (N = 190)
Continuous variables are expressed as means ± SD and median with range. Nominal variables are expressed as percentage. Numbers in parenthesis indicate the
number of patients for whom the corresponding clinical data could be obtained.
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Fig. 2. Influence of the CCR5 ∆32 genotype on renal survival in pa-
tients with IgA nephropathy. Kaplan-Meier plots of renal survival are
shown in months from the date of biopsy until either end stage renal
disease or the last follow up (CCR5 32 genotype vs. wild-type, P <
0.001, Log-rank test).
results from the univariate analysis and revealed a high
independent prognostic value for creatinine at the time
of biopsy [hazard ratio (HR) 1.52; 95% CI 1.38 to 1.68;
P < 0.001] and the CCR5 32 genotype (HR 0.23; 95%
CI 0.09 to 0.57; P = 0.002) (Table 2).
Functional effects of the CCR5 ∆32 mutation
on monocyte chemotaxis
Chemotactic assays were carried out to assess the func-
tional effect of the CCR5 32 mutation on directional
monocyte migration, using the CCR5 ligands MIP-1b
(the only ligand known to be specific for CCR5), MIP-1
a, and RANTES, as well as the CCR2 ligand MCP-1.
Chemotaxis of monocytes toward all tested chemokines
was significantly increased compared to basal conditions
in all three groups (CCR5+/+, CCR5 32/+, and CCR5
32/32) with the exception of 32/32 vs. basal in re-
sponse to MIP-1b (Fig. 3). The chemotactic assays re-
vealed a statistically significant (P < 0.01) reduction of
chemotaxis of monocytes from CCR5 32 carriers in
comparison to CCR5+/+ monocytes in response to MIP-
1 b , MIP-1a, and RANTES. In addition, monocytes from
homozygous 32 carriers had a significantly reduced
chemotactic responsiveness to MIP-1b in comparison to
heterozygous 32 allele carriers (Fig. 3).
Baseline migration and the migratory response toward
the chemokine MCP-1, which binds to the chemokine
receptor CCR2, showed no statistically significant differ-
ences between monocytes of CCR5+/+, CCR5 32/+,
and CCR5 32/32 carriers. These data indicate that
the decreased migration of monocytes from 32 carri-
ers in response to the CCR5 ligands MIP-1 a, MIP-1b ,
and RANTES is caused by the lack or reduction of a
functional receptor specific for these chemokines and not
due to a generally altered migrational behavior of their
monocytes.
DISCUSSION
IgA nephropathy is the most frequent form of glomeru-
lonephritis in the world. Initially believed to have a
benign course, it is now clear that about one third of the
patients with IgA nephropathy develop a progressive loss
of renal function eventually leading to ESRD [3–5]. Some
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Fig. 3. Functional effects of CCR5 ∆32 mutation on chemotaxis. RANTES (100 ng/mL), MIP-1a (100 ng/mL), MIP-1b (100 ng/mL), and MCP-1
(100 ng/mL) induced chemotaxis on freshly isolated monocytes was assessed in a chemotactic assay. The number of migrated M/M under basal
conditions was standardized as 100%. Chemotaxis of monocytes toward all tested chemokines was significantly increased compared to basal
conditions in all three groups with the exception of 32/32 vs. basal in response to MIP-1b . Significance of differences between groups is indicated
as follows: #P < 0.01 +/+ vs. 32/32; ∗P < 0.01 +/+ vs. +/32; †P < 0.01 +/32 vs. 32/32.
Table 2. Cox proportional-hazard analysis to assess the effect of the evaluated factors (serum creatinine, CCR5 32 genotype, proteinuria,
hypertension, gender, and age at the time of biopsy) on renal survival
Univariate analysis Multivariate analysis
Hazard ratio (95% CI); Hazard ratio (95% CI);
Risk factor P value P value
Serum creatinine 1.52 (1.38–1.67); < 0.001 1.52 (1.38–1.68); < 0.001
CCR5 32 genotype 0.29 (0.13–0.62); 0.001 0.23 (0.09–0.57); 0.002
Proteinuria >1 g/24 hours 1.06 (0.66–1.7); 0.83
Hypertension 0.84 (0.5–1.42); 0.51
Gender 1.13 (0.72–1.77); 0.61
Age 1.01 (0.99–1.02); 0.48
P values were derived by the Wald v 2 test. The univariate Cox proportional-hazard analysis of the variables serum creatinine, CCR5 genotype, proteinuria,
hypertension, gender, and age revealed significant influence on renal survival for serum creatinine and CCR5 32 genotype. Multivariate analysis revealed a high
independent prognostic value for creatinine at the time of biopsy as well as the CCR5 32 genotype.
risk factors such as increased serum creatinine, protein-
uria, and arterial hypertension [5, 21] have been identified
to predict for progression of IgA nephropathy. However,
these factors probably account for no more than 30%
of the total risk of disease progression [21]. Therefore,
the identification of other risk factors is of great interest.
The different incidence in various ethnic populations and
the heterogeneous pattern of disease progression sug-
gest that genetic factors could also determine the natural
course of IgA nephropathy [22].
Pathophysiologically the progression to ESRD in pa-
tients with IgA nephropathy is largely correlated with
the infiltration of monocytes and lymphocytes into the
renal tissue [6–8]. Chemokines, a family of chemotac-
tic cytokines, are considered to be the main regulators
of leukocyte trafficking under homeostatic and inflam-
matory conditions [9, 10]. In experimental models of
glomerulonephritis, blockade of the chemokine receptor
CCR5 with neutralizing antibodies or a peptide antago-
nist leads to a reduction in leukocyte recruitment and im-
provement of renal pathology [11, 24]. Studies of tissue
samples from patients with IgA nephropathy revealed
an increased expression of the CCR5 ligands MIP-1a
and RANTES [25, 26] and demonstrated a correlation
80 Panzer et al: The CCR5 32 genotype increased renal survival in IgA nephropathy
between the intensity of renal infiltration of CCR5-
positive leukocytes and disease progression [12]. These
data suggest a possible role of CCR5-bearing mononu-
clear cells attracted by locally produced MIP-1a and
RANTES in the pathogenesis of IgA nephropathy.
A recently identified common 32 bp deletion muta-
tion in the CCR5 gene (CCR5 32) was shown to lead
to a non-functional receptor. Heterozygous CCR5 32
carriers have a reduced CCR5 expression on mononu-
clear cells [27] and when infected with HIV might have
a slower progression rate to acquired immunodeficiency
syndrome (AIDS) [28]. Since the high allele frequency
in the European population cannot be explained through
random genetic drift, this finding suggests an unknown se-
lection advantage of allele carriers [13]. Previous reports
demonstrated a reduced CCR5 32 allele frequency in
patients with asthma [17]. A significantly lower preva-
lence of the CCR5 32 genotype was detected in patients
with severe compared to nonsevere forms of rheumatoid
arthritis [18]. Our findings of a relatively reduced CCR5
32 allele frequency in patients with IgA nephropathy in
comparison to the healthy control group may underscore
the importance of these findings. One might speculate
that CCR5 32 carriers have a decreased risk to develop
IgA nephropathy or that the 32 allele favors less severe
forms of IgA nephropathy, which in many cases might
not be diagnosed (by renal biopsy) due to lack of clinical
risk factors.
In this study, we investigated the effect of the CCR5
32 genotype on the clinical outcome in IgA nephropa-
thy. Comparison of cumulative renal survival with the
Log-rank test demonstrated that renal survival of IgA
nephropathy patients with the CCR5 32 genotype was
significantly longer compared to patients with the CCR5
wild-type genotype (P < 0.001).
We used the multivariate Cox proportional hazard
model to adjust for concomitant risk factors. The results
demonstrated that the CCR532 mutation is an indepen-
dent factor associated with a significantly reduced risk of
ESRD among patients with IgA nephropathy. Indeed,
the CCR5 32 genotype was the second most important
independent prognostic factor for renal survival (after
the serum creatinine level). Unexpectedly, the presence
of hypertension at the time of biopsy, proteinuria (>1 g/
24 hours), and gender had no significant influence on re-
nal survival in our study. This is likely to be due to the
high incidence of these risk factors in our population
(about 72% of the patients had hypertension, at least
67% had proteinuria, and more than 75% were male),
as well as to the use of nominal values for hyperten-
sion and proteinuria, which might not allow a statistical
discrimination.
Due to the small number of homozygous CCR5 32
IgA nephropathy patients in our study (three of 190 pa-
tients), a statistical analysis of this subgroup cannot be
performed. However, the fact that two of the three pa-
tients in this group developed ESRD indicates that the
absence of a functional CCR5 does not completely pro-
tect against disease progression in IgA nephropathy.
Interestingly, the protective effect of the CCR5 32
genotype was most prominent in the first years follow-
ing renal biopsy. There might be several reasons for this
phenomenon. In IgA nephropathy and other forms of
glomerulonephritis, the inflammatory cell-mediated phe-
notype is probably more important in early disease stages.
Since our in vitro studies revealed a significantly reduced
chemotaxis of monocytes from CCR5 32 carriers, it is
tempting to assume that the protective effect is mediated
by a reduced recruitment of CCR5-bearing mononuclear
cells into the renal tissue, leading to an attenuated inflam-
matory response in the kidney. When time progresses, the
inflammatory phenotype changes to a more fibrotic pic-
ture, with renal nephrosclerosis. At this stage, which oc-
curs 5 to 10 years after onset of the disease, inflammatory
mediators may no longer affect the progressive nature of
IgA nephropathy.
This is the first study to demonstrate an independent
protective role of the CCR5 32 genotype for the clini-
cal outcome in a cohort of patients with IgA nephropathy
who showed a high progression rate to ESRD. Because
of the specific characteristics of our study group and the
retrospective nature of our study, the results should be
considered exploratory. Future studies will be necessary
to confirm the protective effect of the CCR5 32 geno-
type in IgA nephropathy in other populations.
APPENDIX
The following German Nephrology center participated in this study.
The number of provided patients by each center is enclosed in paren-
theses.
Universita¨tsklinikum Hamburg Eppendorf : U. Panzer, A. Schnei-
der, O.M. Steinmetz, U. Wenzel, P. Barth, R. Reinking, J.U. Becker, S.
Harendza, G. Zahner, U. Helmchen, R.A.K. Stahl, U. Tenschert, (N =
48); Klinikum der Universita¨t Regensburg and Klinikum der Universita¨t
Mu¨nchen: M. Fischereder, B.K. Kra¨mer, D. Schlo¨ndorff (N = 17); Uni-
versita¨tklinikum Aachen: T. Ostendorf, J Floege (N = 32); Nephrology
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